EBS Emergent BioSolutions Inc
Emergent BioSolutions Inc (EBS) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.2% since its last earnings release on November 2, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Emergent BioSolutions Inc
Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.